Anti-REGN5381 Reference Antibody (Imelciment, RUO) (HB010036)

Name: Anti-REGN5381 Reference Antibody (Imelciment, RUO)
Brand: abinScience
SKU: HB010036
Price: 490 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD): --

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HB010036
Descripción	Anti-REGN5381 Reference Antibody (Imelciment, RUO) (HB010036) is a human monoclonal antibody detecting NPR1/NPR-A. Expressed in Mammalian cells.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	Immunoglobulin (H-gamma4_L-kappa)_G4hCH2CH3
Actividad biológica	Vixticibart specifically binds to human and monkey natriuretic peptide receptor 1 extracellular domain proteins, with no cross-reactivity to mouse natriuretic peptide receptor 1, natriuretic peptide receptor 2, or natriuretic peptide receptor 3, and does not interfere with atrial natriuretic peptide binding to human natriuretic peptide receptor 1 [1]. Vixticibart (10 -12 to 10 -6 M; under conditions supporting binding) dose-dependently binds to human and monkey natriuretic peptide receptor 1-expressing HEK293 cells, with enhanced binding in the presence of atrial natriuretic peptide or brain natriuretic peptide, and EC 50 values ranging from 2.27 to 5.69 nM [1]. Vixticibart (10 -15 to 10 -5 M) dose-dependently agonizes human and monkey natriuretic peptide receptor 1 in a calcium flux bioassay, with EC 50 values ranging from 42.5 to 82.2 nM, and achieves maximum activation comparable to natriuretic peptide ligands at high concentrations [1]. Vixticibart (10 -14 to 10 -5 M) dose-dependently activates human natriuretic peptide receptor 1 to induce cGMP accumulation in HEK293 cells, acts as a partial agonist relative to natriuretic peptide ligands, and shows enhanced activation in the presence of low concentrations of atrial natriuretic peptide or brain natriuretic peptide [1]. Vixticibart (molar excess; overnight at 4°C) binds to the N-terminal domain of human NPR1 dimers, stabilizing an active conformation in the presence of atrial natriuretic peptide and an active-like conformation in the absence of atrial natriuretic peptide, which drives downstream signaling [1]. Vixticibart (1-50 mg/kg; s.c.; single dose) induces a 10-15 mm Hg reduction in systolic blood pressure in normotensive NPR1 hu/hu mice, with dose-dependent duration of effect lasting up to 28 days for the 50 mg/kg dose [1]. Vixticibart (25 mg/kg; i.v.
Sistema de expresión	Mammalian cells
Naturaleza	Recombinant
Objetivo	Vixticibart
Nivel de endotoxinas	< 10 EU/mg as determined by LAL method.
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	CAS: 2845128-05-2
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	Idiotypic, 2845128-03-0
Fondo	Atrial natriuretic peptide receptor 1 (NPR1/NPR-A) is a ~118 kDa protein. Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Plays an essential role in the regulation of endothelial cell senescence and vascular aging. Upon activation by ANP or BNP, stimulates the production of cyclic guanosine monophosphate (cGMP) that promotes vascular tone and volume homeostasis by activation of protein kinase cGMP-dependent 1/PRKG1 and subsequently PRKAA1, thereby controlling blood pressure and maintaining cardiovascular homeostasis. 1. Liu, S. et al. (2025) Nature structural & molecular biology 32, 469-478. PMID: 39543315 2. Long, C. et al. (2022) Aging cell 21, e13699. PMID: 36016499
Referencias	1. Dunn ME, et al. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature. 2024;633(8030):654-661. [HB010036] 2. Dunn M, et al. A novel agonist antibody to membrane-bound guanylate cyclase receptor, natriuretic peptide receptor 1, induces sustained vasodilation[J]. 2023. [HB010036] 3. Kithcart A P, et al. Effects of REGN5381, a natriuretic peptide receptor 1 agonist antibody, in hypertensive mouse models and mildly hypertensive but otherwise healthy adults in a phase 1 first-in-human study[J]. Journal of the American College of Cardiology, 2024, 83(13_Supplement): 1706-1706. [HB010036]
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207)

Imágenes

SDS-PAGE

SDS-PAGE for Research Grade Imelciment

Referencias

Datasheet

Anti-REGN5381 Reference Antibody (Imelciment, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Proteínas Recombinantes

Anticuerpos

Kits de Ensayo

Anti-REGN5381 Reference Antibody (Imelciment, RUO) (HB010036)

Vista general

Imágenes

Referencias

Datasheet

SDS